Coronary Plaque Progression After Androgen Deprivation Therapy in Men With Prostate Cancer: the REVELUTION Trial with Sagar Patel

Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity. Recent studies have demonstrated a mixed signal for the comparative cardiovascular safety of gonadotropin releasing hormone (GnRH) agonists versus antagonists. The REVELUTION Trial randomized prostate cancer patients to GnRH agonists versus antagonists and compared coronary CT plaque progression.

Learn more here.